[ASAP] Design, Synthesis, and Biological Evaluation of Novel Diaminopyrimidine Macrocycles as Fourth Generation Reversible EGFR Inhibitors That Overcome Clinical Resistance to Osimertinib Mediated by C797S Mutation 🔗 Access full article via ACS Journal of Medicinal ChemistryShare:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon